Minocycline controlled-release - OraPharma

Drug Profile

Minocycline controlled-release - OraPharma

Alternative Names: Arestin; Arestin LCM; Minocycline microspheres

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator Wyeth
  • Developer OraPharma; Wyeth
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Periodontitis
  • Discontinued Peri-implantitis

Most Recent Events

  • 09 Aug 2016 Discontinued - Phase-III for Peri-implantitis in United Kingdom, Sweden, Germany and USA (Subgingival) based on analysis of a phase III study data (Valeant Pharmaceuticals Form10-Q, August 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 24 Jun 2014 OraPharma completes a phase III trial in Peri-implantitis in USA, United Kingdom, Germany & Sweden (NCT01539564)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top